The Value of Tumour Markers in the Detection of Relapse—Lessons Learned from the Swiss Austrian German Testicular Cancer Cohort Study

Fischer, Stefanie; Rothermundt, Christian; Stalder, Odile; Terbuch, Angelika; Hermanns, Thomas; Zihler, Deborah; Müller, Beat; Fankhauser, Christian Daniel; Hirschi-Blickenstorfer, Anita; Seifert, Bettina; Kluth, Luis A.; Ufe, Mark-Peter; Mingrone, Walter; Templeton, Arnoud J.; Fischer, Natalie; Rothschild, Sacha I.; Woelky, Regina; Gillessen, Silke; Cathomas, Richard

doi:10.1016/j.euros.2023.01.013

Cited by 10 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HCG levels are often used in combination with AFP to diagnose and monitor testicular cancer. Studies have found that HCG levels can be a significant predictor of relapse in patients with testicular cancer [65,66]. (3) Lactate dehydrogenase (LDH): Elevated levels of LDH are associated with testicular cancer, and this metabolic enzime is often used as a predictor of overall survival in patients [64].…”

Section: Biomarkers In Testicular Cancers: Use In Early Detection Dia...mentioning

confidence: 99%

Epigenetic Factors and ncRNAs in Testicular Cancer

Nuñez-Corona,

Contreras-Sanzón,

Puente-Rivera

et al. 2023

IJMS

View full text Add to dashboard Cite

Testicular cancer is the most prevalent tumor among males aged 15 to 35, resulting in a significant number of newly diagnosed cases and fatalities annually. Non-coding RNAs (ncRNAs) have emerged as key regulators in various cellular processes and pathologies, including testicular cancer. Their involvement in gene regulation, coding, decoding, and overall gene expression control suggests their potential as targets for alternative treatment approaches for this type of cancer. Furthermore, epigenetic modifications, such as histone modifications, DNA methylation, and the regulation by microRNA (miRNA), have been implicated in testicular tumor progression and treatment response. Epigenetics may also offer critical insights for prognostic evaluation and targeted therapies in patients with testicular germ cell tumors (TGCT). This comprehensive review aims to present the latest discoveries regarding the involvement of some proteins and ncRNAs, mainly miRNAs and lncRNA, in the epigenetic aspect of testicular cancer, emphasizing their relevance in pathogenesis and their potential, given the fact that their specific expression holds promise for prognostic evaluation and targeted therapies.

show abstract

Section: Biomarkers In Testicular Cancers: Use In Early Detection Dia...mentioning

confidence: 99%

Epigenetic Factors and ncRNAs in Testicular Cancer

Nuñez-Corona,

Contreras-Sanzón,

Puente-Rivera

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Additionally, 124 patients (15.6%) experienced at least one false-positive marker elevation, defined as a positive marker result in a patient who remained free from a proven relapse for at least 6 months after the incident. These false-positive results can lead to unnecessary additional imaging or a hesitancy to investigate further due to the perceived irrelevance of the marker elevations [13]. Another study conducted in 2020 reviewed the records of 794 patients with GCTs treated in three Spanish hospitals and found that of the 125 patients who developed a first recurrence, 123 had marker levels recorded.…”

Section: Introductionmentioning

confidence: 99%

Advancing GCT Management: A Review of miR-371a-3p and Other miRNAs in Comparison to Traditional Serum Tumor Markers

Seales,

Puri,

Yodkhunnatham

et al. 2024

Cancers

View full text Add to dashboard Cite

MicroRNAs, short non-protein coding RNAs, are overexpressed in GCTs. Circulating levels of germ cell tumor (GCT)-associated miRNAs, such as miR-371a-3p, can be utilized as efficient and cost-effective alternatives in diagnosing and managing patients presenting with GCTs. This quality of miRNAs has demonstrated favorable performance characteristics as a reliable blood-based biomarker with high diagnostic accuracy compared to current serum tumor markers (STMs), including α-fetoprotein (AFP), beta human chorionic gonadotropin (β-hCG), and lactate dehydrogenase (LDH). The conventional STMs exhibit limited specificity and sensitivity. Potential clinical implications of miRNAs include impact on de-escalating or intensifying treatment, detecting recurrence at earlier stages, and lessening the necessity of cross-sectional imaging or invasive tissue biopsy for non-teratomatous GCTs. Here, we also highlight the outstanding issues that must be addressed prior to clinical implementation. Standards for measuring circulating miRNAs and determining ideal cutoff values are essential for integration into current clinical guidelines.

show abstract

“…Alpha fetoprotein (AFP) or cancer embryo antigen (CEA) can be used as characteristic markers in the early diagnosis of gastric cancer, lung cancer, breast cancer, etc. [18][19][20]. So far, there are more than 160 different types of tumor markers that can be used for the diagnosis of early-stage cancer patients, including hydrogen peroxide (H 2 O 2 ), glutathione (GSH), and other biomolecule compounds [21][22][23], CTC [24], exosomes engaged in regulating cell waste disposal and intercellular communication, etc.…”

Section: Introduction For Tumor Markersmentioning

confidence: 99%

Application of Metal-Based Nanomaterials in In Vitro Diagnosis of Tumor Markers: Summary and Prospect

2023

View full text Add to dashboard Cite

Cancer, which presents with high incidence and mortality rates, has become a significant health threat worldwide. However, there is currently no effective solution for rapid screening and high-quality treatment of early-stage cancer patients. Metal-based nanoparticles (MNPs), as a new type of compound with stable properties, convenient synthesis, high efficiency, and few adverse reactions, have become highly competitive tools for early cancer diagnosis. Nevertheless, challenges such as the difference between the microenvironment of detected markers and the real-life body fluids remain in achieving widespread clinical application of MNPs. This review provides a comprehensive review of the research progress made in the field of in vitro cancer diagnosis using metal-based nanoparticles. By delving into the characteristics and advantages of these materials, this paper aims to inspire and guide researchers towards fully exploiting the potential of metal-based nanoparticles in the early diagnosis and treatment of cancer.

show abstract

The Value of Tumour Markers in the Detection of Relapse—Lessons Learned from the Swiss Austrian German Testicular Cancer Cohort Study

Cited by 10 publications

References 10 publications

Epigenetic Factors and ncRNAs in Testicular Cancer

Epigenetic Factors and ncRNAs in Testicular Cancer

Advancing GCT Management: A Review of miR-371a-3p and Other miRNAs in Comparison to Traditional Serum Tumor Markers

Application of Metal-Based Nanomaterials in In Vitro Diagnosis of Tumor Markers: Summary and Prospect

Contact Info

Product

Resources

About